Literature DB >> 30929012

Rituximab bioavailability in primary membranous nephropathy.

Sonia Boyer-Suavet1, Marine Andreani1, Marion Cremoni2, Vesna Brglez1,2, Sylvia Benzaken2, Ghislaine Bernard2, Patrick Nachman3, Vincent Esnault1, Barbara Seitz-Polski1,2,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30929012     DOI： 10.1093/ndt/gfz041

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  11 in total

Review 1.  Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy.

Authors:  Maxime Teisseyre; Marion Cremoni; Sonia Boyer-Suavet; Caroline Ruetsch; Daisy Graça; Vincent L M Esnault; Vesna Brglez; Barbara Seitz-Polski
Journal:  Front Immunol       Date:  2022-05-04       Impact factor: 8.786

Review 2.  Rituximab in Membranous Nephropathy.

Authors:  Philipp Gauckler; Jae Il Shin; Federico Alberici; Vincent Audard; Annette Bruchfeld; Martin Busch; Chee Kay Cheung; Matija Crnogorac; Elisa Delbarba; Kathrin Eller; Stanislas Faguer; Kresimir Galesic; Siân Griffin; Martijn W F van den Hoogen; Zdenka Hrušková; Anushya Jeyabalan; Alexandre Karras; Catherine King; Harbir Singh Kohli; Gert Mayer; Rutger Maas; Masahiro Muto; Sergey Moiseev; Balazs Odler; Ruth J Pepper; Luis F Quintana; Jai Radhakrishnan; Raja Ramachandran; Alan D Salama; Ulf Schönermarck; Mårten Segelmark; Lee Smith; Vladimír Tesař; Jack Wetzels; Lisa Willcocks; Martin Windpessl; Ladan Zand; Reza Zonozi; Andreas Kronbichler
Journal:  Kidney Int Rep       Date:  2021-01-13

3.  Analysis and Management of Rituximab Resistance in PLA2R1-Associated Membranous Nephropathy.

Authors:  Maxime Teisseyre; Sonia Boyer-Suavet; Marion Crémoni; Vesna Brglez; Vincent Esnault; Barbara Seitz-Polski
Journal:  Kidney Int Rep       Date:  2021-01-29

Review 4.  Perspectives in membranous nephropathy.

Authors:  Nicola M Tomas; Tobias B Huber; Elion Hoxha
Journal:  Cell Tissue Res       Date:  2021-04-06       Impact factor: 4.051

5.  Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome.

Authors:  Quentin Bertrand; Sabine Mignot; Theresa Kwon; Anne Couderc; Anne Maisin; Alexandra Cambier; Véronique Baudouin; Marine Peyneau; Georges Deschênes; Julien Hogan; Claire Dossier
Journal:  Pediatr Nephrol       Date:  2021-06-16       Impact factor: 3.714

6.  Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.

Authors:  Giuseppe Stefano Netti; Barbara Infante; Federica Spadaccino; Giulia Godeas; Maria Grazia Corallo; Concetta Prisciandaro; Laura Croce; Mario Rotondi; Loreto Gesualdo; Giovanni Stallone; Giuseppe Grandaliano; Elena Ranieri
Journal:  J Immunol Res       Date:  2019-11-05       Impact factor: 4.818

Review 7.  Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?

Authors:  Lucia Del Vecchio; Marco Allinovi; Paolo Rocco; Bruno Brando
Journal:  J Clin Med       Date:  2021-12-13       Impact factor: 4.241

Review 8.  B Cells in Primary Membranous Nephropathy: Escape from Immune Tolerance and Implications for Patient Management.

Authors:  Benjamin Y F So; Desmond Y H Yap; Tak Mao Chan
Journal:  Int J Mol Sci       Date:  2021-12-17       Impact factor: 5.923

9.  Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.

Authors:  Maxime Teisseyre; Marion Cremoni; Sonia Boyer-Suavet; Thomas Crepin; Sylvia Benzaken; Kévin Zorzi; Vincent Esnault; Vesna Brglez; Barbara Seitz-Polski
Journal:  Front Immunol       Date:  2021-10-13       Impact factor: 7.561

10.  Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease.

Authors:  Diankun Liu; Zhanmei Zhou; Mengyi Wang; Sheng Nie; Jun Li; Bianxiang Hu; Wenjuan He; Guobao Wang; Jun Ai
Journal:  BMC Nephrol       Date:  2021-07-01       Impact factor: 2.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.